TY - JOUR
T1 - Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality
T2 - A Population-Based Cohort Study
AU - Kim, Kyung Soo
AU - Hong, Sangmo
AU - Ahn, Hong Yup
AU - Park, Cheol Young
N1 - Publisher Copyright:
© 2023 Korean Diabetes Association. All rights reserved.
PY - 2023/3
Y1 - 2023/3
N2 - Background: We investigated whether metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with an elevated risk of all-cause and cardiovascular mortality using a large-scale health examination cohort. Methods: A total of 394,835 subjects in the Kangbuk Samsung Health Study cohort were enrolled from 2002 to 2012. Participants were categorized by the presence of nonalcoholic fatty liver disease (NAFLD) and MAFLD as follows: normal subjects; patients with both NAFLD and MAFLD; patients with NAFLD only; and patients with MAFLD only. Cox proportional hazards models were used to analyze the risk of mortality. Results: During a median 5.7 years of follow-up, 20.69% was patients with both NAFLD and MAFLD, 1.51% was patients with NAFLD only, and 4.29% was patients with MAFLD only. All-cause and cardiovascular death was higher in patients with MAFLD than those without MAFLD (P<0.001, respectively). In patients with MAFLD only, the hazard ratio (HR) of all-cause and cardiovascular death was 1.35 (95% confidence interval [CI], 1.13 to 1.60) and 1.90 (95% CI, 1.26 to 2.88) after adjusting for age, which lost its statistical significance by multivariable adjustments. Compared to patients with less than two components of metabolic dysfunction, patients with more than two components of metabolic dysfunction were a higher risk of cardiovascular death (HR, 2.05; 95% CI, 1.25 to 3.38) and only women with more than two components of metabolic dysfunction were a higher risk of all-cause death (HR, 1.44; 95% CI, 1.02 to 2.03). Conclusion: MAFLD criteria could identify a high-risk group for all-cause and cardiovascular death.
AB - Background: We investigated whether metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with an elevated risk of all-cause and cardiovascular mortality using a large-scale health examination cohort. Methods: A total of 394,835 subjects in the Kangbuk Samsung Health Study cohort were enrolled from 2002 to 2012. Participants were categorized by the presence of nonalcoholic fatty liver disease (NAFLD) and MAFLD as follows: normal subjects; patients with both NAFLD and MAFLD; patients with NAFLD only; and patients with MAFLD only. Cox proportional hazards models were used to analyze the risk of mortality. Results: During a median 5.7 years of follow-up, 20.69% was patients with both NAFLD and MAFLD, 1.51% was patients with NAFLD only, and 4.29% was patients with MAFLD only. All-cause and cardiovascular death was higher in patients with MAFLD than those without MAFLD (P<0.001, respectively). In patients with MAFLD only, the hazard ratio (HR) of all-cause and cardiovascular death was 1.35 (95% confidence interval [CI], 1.13 to 1.60) and 1.90 (95% CI, 1.26 to 2.88) after adjusting for age, which lost its statistical significance by multivariable adjustments. Compared to patients with less than two components of metabolic dysfunction, patients with more than two components of metabolic dysfunction were a higher risk of cardiovascular death (HR, 2.05; 95% CI, 1.25 to 3.38) and only women with more than two components of metabolic dysfunction were a higher risk of all-cause death (HR, 1.44; 95% CI, 1.02 to 2.03). Conclusion: MAFLD criteria could identify a high-risk group for all-cause and cardiovascular death.
KW - Fatty liver
KW - Metabolic syndrome
KW - Mortality
KW - Non-alcoholic fatty liver disease
UR - http://www.scopus.com/inward/record.url?scp=85148717222&partnerID=8YFLogxK
U2 - 10.4093/DMJ.2021.0327
DO - 10.4093/DMJ.2021.0327
M3 - Article
C2 - 36631994
AN - SCOPUS:85148717222
SN - 2233-6079
VL - 47
SP - 220
EP - 231
JO - Diabetes and Metabolism Journal
JF - Diabetes and Metabolism Journal
IS - 2
ER -